Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)

Trial Profile

Phase 2 study of Pemetrexed + Carboplatin + Bevacizumab as first line therapy for nonsquamous non-small cell lung cancer with EGFR Mutation (CJLSG0910)

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Jul 2015 New trial record
    • 02 Jun 2015 Status changed from active, no longer recruiting to completed, based on results presented at ASCO 2015.
    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top